Sowing the seeds for future growth



At Merck Animal Health we never lose sight of the fact that innovation is the lifeblood of our industry. In today’s highly competitive markets we need to invest heavily to achieve success with tomorrow’s products. Our Animal Health portfolio reflects our unwavering commitment to R&D. The result is a pipeline, which in terms of size and quality, provides us with a solid platform for consistent growth in veterinary vaccines and pharmaceuticals.

A well–balanced pipeline requires scientific rigor and innovation as well as astute management. In pharmaceutical R&D, we have 120 ongoing projects focusing on parasiticides, anti-infectives and internal medicine (endocrine/pain) and performance products. Meanwhile in biological R&D, we have 140 projects in progress focusing on zoonotic and emerging diseases, respiratory diseases, enteric diseases and enabling technologies.

All this would not be possible without our R&D facilities which consist of four major vaccine research sites and three major pharmaceutical research sites around the world. We also have research operations close to the markets. This enables us to focus on local diseases and issues and respond quickly to changing market needs. In today’s business environment no company can afford to go it alone. We actively seek to leverage our in-house R&D expertise with a forward-thinking business development and in-licensing program and are constantly looking to partner with specialist biotech companies, universities and research institutions to develop and market innovative animal health products. We also collaborate closely with colleagues in human health to learn how we can share best practice and, at the same time, fully exploit the innovative power of our science base.

Our company has vaccine manufacturing sites in all regions of the world to address the specific regional disease needs. Our commitment to cell culture technology is evident from the substantial vaccine manufacturing capacity available at our Boxmeer (NL), De Soto (USA) and Burgwedel (Germany) sites. We recently extended our vaccine franchise and expertise by opening a new SPHEREON vaccine manufacturing facility in Boxmeer. The in-house developed SPHEREON technology freeze-dries live poultry vaccines to small, highly soluble particles (spheres) instead of the traditional vaccine cake in a glass bottle. Our customers come first. And that is why we dedicate so much time and energy to developing and maintaining close contacts with the veterinarians, farmers and animal owners who use our products. Guided by them, we aim to offer products that are more than just effective tools for the treatment and control of disease. Our goal is to go one step further. We strive to develop effective and easy-to-administer products that help improve the health of animals, add value to the businesses of the owners and help to drive up standards in overall animal care.